New Study Reveals Potential Breakthrough for Psoriasis Treatment
New Study Reveals Potential Breakthrough for Psoriasis Treatment
New Study Reveals Potential Breakthrough for Psoriasis Treatment
A recent study has uncovered a potential new target for treating inflammatory skin diseases like psoriasis. Researchers identified G protein-coupled estrogen receptor 1 (GPER1) as a key regulator of skin cell growth. This discovery could pave the way for more selective and safer therapies in the future.
The study, published in Cell Death Discovery, reveals that GPER1 plays a crucial role in skin health. Previously, its functions were linked mainly to cardiovascular health, metabolism, and certain cancers. However, its involvement in skin inflammation had remained unexplored until now.
Tests on animal models showed that activating GPER1 reduced the severity of psoriasis-like skin inflammation. The receptor also lowered histopathological markers of the disease. One key finding was that GPER1 activation slowed keratinocyte proliferation, particularly during the G1 phase of the cell cycle.
The receptor works by interfering with the MAPK/ERK pathway, cutting down the production of pro-inflammatory signals like TNF-α and IL-6. Because GPER1 operates through a non-genomic mode of action, it triggers rapid cellular responses. This makes it a promising candidate for developing new treatments.
Researchers suggest that GPER1 agonists could be developed into topical or systemic drugs for managing skin inflammation. Unlike broader treatments, targeting GPER1 may offer a more precise approach with fewer side effects. Additionally, measuring GPER1 levels or activity in patients could help tailor therapies in personalised medicine.
As of March 2026, no clinical trials testing GPER1 agonists for psoriasis or similar conditions in humans have been recorded in public databases like ClinicalTrials.gov.
The findings highlight GPER1's potential as a therapeutic target for inflammatory skin diseases. Further research and eventual clinical trials will determine whether GPER1 agonists can become viable treatments. For now, the study underscores the receptor's broader role in skin physiology and pathology.